Titre :

Amantadine use in the French prospective NS-Park cohort

Auteur(s) :

Fabbri, Margherita [Auteur]
Rousseau, Vanessa [Auteur]
Corvol, Jean-Christophe [Auteur]
Sommet, Agnès [Auteur]
Tubach, Florence [Auteur]
De Rycke, Yann [Auteur]
Bertille, Nathalie [Auteur]
Selvarasa, Yajiththa [Auteur]
Carvalho, Stephanie [Auteur]
Chaigneau, Véronique [Auteur]
Brefel-Courbon, Christine [Auteur]
Ory-Magne, Fabienne [Auteur]
Tessier, Samuel [Auteur]
Tir, Melissa [Auteur]
Bereau, Matthieu [Auteur]
Meissner, Wassilios G. [Auteur]
Thiriez, Claire [Auteur]
Marques, Ana [Auteur]
Remy, Philippe [Auteur]
Schneider, Vincent [Auteur]
Moro, Elena [Auteur]
Defebvre, Luc [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Houeto, Jean Luc [Auteur]
Prange, Stephane [Auteur]
Eusebio, Alexandre [Auteur]
Geny, Christian [Auteur]
Frismand, Solène [Auteur]
Damier, Philippe [Auteur]
Reuther, Caroline Giordana [Auteur]
Castelnovo, Giovanni [Auteur]
Benatru, Isabelle [Auteur]
De Maindreville, Anne Doe [Auteur]
Drapier, Sophie [Auteur]
Maltête, David [Auteur]
Lagha-Boukbiza, Ouhaid [Auteur]
Rascol, Olivier [Auteur]

Titre de la revue :

Journal of Neural Transmission

Nom court de la revue :

J Neural Transm (Vienna)

Numéro :

131

Pagination :

799–811

Éditeur :

Springer Verlag

Date de publication :

2024-04-05

ISSN :

1435-1463

Mot(s)-clé(s) en anglais :

Parkinson's disease
Amantadine
NS-Park
Motor complications

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Médecine humaine et pathologie

Résumé en anglais : [en]

Objective : To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD). Background : Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical ...
Lire la suite >Objective : To assess amantadine use and associated factors in the patients with Parkinson’s disease (PD). Background : Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat “levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. Methods : Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). Results : Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12–18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. Conclusions : About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Équipe(s) de recherche :

Troubles cognitifs dégénératifs et vasculaires

Date de dépôt :

2024-06-22T21:24:33Z
2025-02-25T13:31:02Z